Treating to Target in Patients with Gout and Chronic Kidney Disease: A Patient Simulation
Click Here To Download Patient Resources (PDF)
Premiere Date: Wednesday, April 12, 2017This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- Nurse Practitioners (AANP)
- Physician Assistants (AAPA)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, April 12, 2018
Note: Credit Is No Longer Available
 | Allan Gibofsky, MD, JD, MACR, FACP, FCLM (Moderator) Professor of Medicine Weill Cornell Medicine Attending Rheumatologist Co-Director, Clinic for Inflammatory Arthritis Hospital for Special Surgery New York, NY |
 | Theodore R. Fields, MD, FACP Professor of Clinical Medicine Weill Cornell Medical College Director, Rheumatology Faculty Practice Plan Hospital for Special Surgery New York, NY |
 | Eva Hardy, MS, RN, ANP-BC Department of General Orthopedic Surgery Presbyterian Health Services Presbyterian Rust Medical Center Rio Rancho, NM |
Gout is the most common form of inflammatory arthritis in the United States.1 Hyperuricemia/gout in patients with CKD constitutes a significant burden for patients and society. Patients who are not managed adequately experience painful gout attacks, loss of function and productivity, and may develop long-term complications. The economic burden is also increased from patient utilization of prescription medication use, emergency room visits, and hospitalizations from gout or its serious complications.
Despite effective treatment for prevention, acute attacks, and tophi, and the availability of published treatment guidelines, there are significant gaps in treatment, patient communication, and clinical and economic outcomes for patients with hyperuricemia/gout and chronic kidney disease (CKD).
In this CME Outfitters decision-tree medical simulation participants will navigate the clinical challenges presented by a patient with gout and chronic kidney disease. Along the way, expert faculty will provide guidance, insights, and evidence for the positive and negative consequences of their decisions. This actionable, evidence-based simulation will improve clinician confidence in their ability to recognize and assess patients with hyperuricemia or gout, improve coordination of care among healthcare providers, and develop personalized treatment plans for managing their patients.
Reference:
1. Mandell B, Keenan R. So you think you know gout? Fresh perspectives on hyperuricemia for today’s complicated patients. Medscape Website. http://www.medscape.org/viewarticle/837667. Published January 30, 2015.
At the end of this CE activity, participants should be able to:
- Execute strategies to enhance an understanding of the association among hyperuricemia, gout, and CKD.
- Utilize educational resources in shared decision-making discussions with patients to promote medication adherence and optimize outcomes.
- Implement strategies to achieve optimal clinical and economic outcomes in patients with hyperuricemia or gout and CKD.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Physicians, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals with an interest in gout and chronic kidney disease.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP Credit (Nurse Practitioners):
This activity is approved 1.0 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 17032596. This activity was planned in accordance with AANP CE Standards and Policies
AAPA Credit (Physician Assistants):
his program has been reviewed and is approved for a maximum of 1.00 AAPA Category 1 CME credits by the AAPA Review Panel. Approval is valid for one year from the issue date of 04/07/2017. Participants may submit the post-test at any time during that period.
This program was planned in accordance with AAPA CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1 contact hour
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1 contact hours of pharmacotherapeutic contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.10 CEUs) Universal Activity Number:
0376-0000-17-013-H01-P
Type: practice-based
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST21227 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gibofsky has reported that he serves on the speakers bureau for AbbVie Inc.; Amgen Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and UCB, Inc. He is a consultant for AbbVie; Amgen Inc.;Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.;Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He is a stock shareholder of AbbVie Inc.; Amgen Inc.; GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.
Dr. Fields has disclosed that he serves on the speakers bureau for Takeda Pharmaceuticals, U.S.A., Inc. He is on the advisory board for Horizon Pharmaceuticals and Takeda Pharmaceuticals, U.S.A., Inc.
Ms. Hardy has no disclosures to report.
Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.
Kimberley Murray, RN, MS (peer reviewer) has no disclosures to report.
Daniela V. DiBiase, MS (planning committee) has no disclosures to report.
Jan Perez, CCHP (planning committee) has no disclosures to report.
Sharon Tordoff, CCHP (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to Disclose
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
PL-054-030817-20
